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We have designed, developed and produced a lambda-
phage based therapeutic anti-cancer vaccine (nanoparticle)
targeting human aspartyl (asparaginyl) b-hydroxylase
(HAAH). This protein is over-expressed on the surface of
cancer cells and plays a central role in cancer etiology that
affects cancer cell growth, motility and invasiveness.
To overcome the self-antigen tolerance of the molecule,
we have designed a vaccine entity that contains an immu-
nostimulant and presents HAAH in a manner that is
unfamiliar to the body. We have expressed three portions
of the HAAH protein, sequences from the N-terminus,
middle portion and C-terminus, as fusion proteins (with
the gpD bacteriophage antigen) on the surface of bacter-
iophage lambda, generating 200-300 copies per phage. All
three entities display highly significant, dose-dependent
immunogenicity as assessed by antibody ELISAs. To
evaluate the therapeutic effect of the nanoparticle vaccine,
we initiated tumor formation in BALB/c mice using a
mouse hepatocellulular carcinoma cell line, BNLT3. This
cell line, a highly tumorigenic subclone of the ATCC cell
line, BNL 1ME A.7R.1, was developed by J. Wands at the
Liver Research Center, Rhode Island Hospital by three
serial subcutaneous passages of the parental cell line. On
Day 0 of the tumor challenge study, 4 groups of 5 mice
each were administered 5E03 BNLT3 cells subcutaneously.
On the same day, the animals received the first of three
weekly subcutaneous doses (i.e., Days 0, 7 and 14) of
nanoparticle vaccine as monovalent vaccines of each of
the three bacteriophage constructs (10E10 pfu/dose) or a
buffer control. The mice were then observed for tumor
growth and tumor volume was determined. After 4 weeks
(Study Day 28), 3 of 5 mice in the control group
had measurable tumor growth, while in the HAAH N-
terminus, middle portion and C-terminus construct vac-
cine groups, 0/5, 2/5 and 0/5 animals, respectively, had
measurable tumor growth. The mean tumor volumes of
the 5 animals in each of the two groups with tumor
growth were 85.8 mm3 for the control group and 24.9
mm3 (29 % of control tumor volume) for the HAAH
middle portion group. Overall, the vaccinated groups
had growth in 2/15 animals and mean tumor growth of
8.3 mm3 (> 10 % of the control group tumor size).
We are continuing to evaluate the HAAH nanoparticle
vaccines in the mouse tumor model under various con-
ditions and combinations of constructs. We are also
assessing study samples for cell-based immunity as we
attempt to elicit the mechanism of action for this vac-
cine candidate. We are also taking all the required steps
in preparation for an IND submission to FDA.
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